CompanyALMSNasdaqSouth San Francisco, CA

Alumis Inc

Alumis develops oral tyrosine kinase 2 inhibitors for immune-mediated diseases.

SEC EDGAR ClinicalTrials.gov alumis.com

8-KSep 1Latest SEC filing, period to Sep 1

Sep 1Latest story

September 2026

Alumis' LUMUS trial misses main goals in lupus, but subgroup shows benefit

Sep 1Clinical readoutAlumis Inc envudeucitinib

August 2026

Alumis reports long-term ONWARD3 data, keeps NDA and LUMUS timelines on track

Aug 13Quarterly updateAlumis Inc envudeucitinib